# A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

> **NCT04200248** · PHASE2 · COMPLETED · sponsor: **Ribomic USA Inc** · enrollment: 94 (actual)

## Conditions studied

- Exudative Age-related Macular Degeneration

## Interventions

- **DRUG:** RBM-007 Injectable Solution
- **DRUG:** Aflibercept
- **DRUG:** Sham

## Key facts

- **NCT ID:** NCT04200248
- **Lead sponsor:** Ribomic USA Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-02
- **Primary completion:** 2021-11-19
- **Final completion:** 2021-12-22
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04200248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04200248, "A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04200248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*